NASDAQ : RPRX

Royalty Pharma plc

$58.83 USD

-$0.19 (-0.32%)

Volume
2.11M
Average Volume
3.75M
Market Capitalization
$25.3B
P/E Ratio
23.87
Dividend Yield
1.55%
Price Target
$57.00
Year High
$59.72
Year Low
$34.08
Day High
—
Day Low
—
Payout Ratio
$0.47
Current Ratio
$2.66
Company Overview

NASDAQ

Pablo Legorreta

Medical - Pharmaceuticals

Healthcare

RPRX

100

US

USD

https://www.royaltypharma.com

212 883 0200

G7709Q104

0001802768

Liquidity Metrics

1.30

2.66

2.66

1.09

0.47

Sales & Valuation

$2.38B

10.37

3.69

9.53

6.15

Profitability

$1.8

$770.95M

33.91%

55.69%

12.67%

4.18%

P/E Metrics

23.87

-58.97

-58.97

Analyst Price Target & Rating

$57.00

$63.00

$50.00

Neutral

3/5

11 Analysts

3.21%

Financial Health Scores

2.17

7/9

$890.13M

$19.82B

$9.88B

$1.7B

Key Metrics (TTM)

$33.76B

13.83

19.87

2.66

12.67%

8.43%

3.25%

10.46%

$26.22

-7822 days

Company Executives
Name Title
James Folmar Reddoch Executive Vice President of Investments & Chief Scientific Officer
George Grofik Senior Vice President and Head of Investor Relations & Communications
Pablo Legorreta Founder, Chairman of the Board & Chief Executive Officer
Molly Sawaya Executive Vice President & Head of Human Capital
Sara Klymkowsky Senior Vice President of Research & Investments
Terrance Coyne Executive Vice President & Chief Financial Officer
Christopher Hite Chairman of Partnering & Investments
Eric Cornelius Schneider Senior Vice President & Chief Technology Officer
Sandy Balkin Senior Vice President of Strategy & Analytics
Sam Landsberg Finance and Treasurer
Kenneth Siming Sun Senior VP & Head of Asia
Ashwin Pai Executive Vice President of Investments & Partnering
Marshall Urist Executive Vice President of Research & Investments
Arthur Richard McGivern Executive Vice President of Investments & Chief Scientific Officer
Lucas Glass Head of Artificial Intelligence
Scott Raichilson Chief Accounting Officer
Poll Results

No votes yet today — be the first to share your view!

About Royalty Pharma plc (NASDAQ:RPRX) Stock

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. ...

Bank of New York Mellon Corp Reduces Stock Position in Royalty Pharma PLC $RPRX

2026-07-23 04:07:27

Bank of New York Mellon Corp decreased its position in Royalty Pharma PLC (NASDAQ: RPRX) by 2.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,302,043 shares of the biopharmaceutical company's stock after selling 37,662 shares during the quarter. Bank of New

Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune

2026-07-22 07:05:00

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront.

Royalty Pharma PLC $RPRX Holdings Lowered by AlTi Global Inc.

2026-07-21 03:13:54

AlTi Global Inc. trimmed its position in Royalty Pharma PLC (NASDAQ: RPRX) by 50.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,073 shares of the biopharmaceutical company's stock after selling 25,554 shares during the period. AlTi Global Inc.'s holdings in

Chicago Partners Investment Group LLC Purchases New Position in Royalty Pharma PLC $RPRX

2026-07-19 04:11:12

Chicago Partners Investment Group LLC purchased a new stake in Royalty Pharma PLC (NASDAQ: RPRX) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 10,756 shares of the biopharmaceutical company's stock, valued at approximately $535,000. Other institutional investors have also added to or

Royalty Pharma declares third quarter 2026 dividend

2026-07-17 16:15:00

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

2026-07-17 10:01:25

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026

2026-07-15 16:15:00

NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

2026-07-13 09:56:19

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Frequently Asked Questions

What is the current Royalty Pharma plc (RPRX) stock price?

Royalty Pharma plc(NASDAQ:RPRX) stock price is $58.83 in the last trading session. During the trading session, RPRX stock reached the peak price of $59.72 while $34.081 was the lowest point it dropped to. The percentage change in RPRX stock occurred in the recent session was --0.32% while the dollar amount for the price change in RPRX stock was -$0.19.

RPRX's industry and sector of operation?

The NASDAQ listed RPRX is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.

Who are the executives of RPRX?

James Folmar Reddoch | Executive Vice President of Investments & Chief Scientific Officer
George Grofik | Senior Vice President and Head of Investor Relations & Communications
Pablo Legorreta | Founder, Chairman of the Board & Chief Executive Officer
Molly Sawaya | Executive Vice President & Head of Human Capital
Sara Klymkowsky | Senior Vice President of Research & Investments

How many employees does RPRX have?

Number of RPRX employees currently stands at 100. RPRX operates from 110 East 59th Street, New York, NY 10022, US.

Link for RPRX official website?

Official Website of RPRX is: https://www.royaltypharma.com

How do I contact RPRX?

RPRX could be contacted at phone #212 883 0200 and can also be accessed through its website. RPRX operates from 110 East 59th Street, New York, NY 10022, US.

How many shares of RPRX are traded daily?

The average number of RPRX shares traded daily for last 3 months was 3.75M.

What is the market cap of RPRX currently?

The market value of RPRX currently stands at $25.3B with its latest stock price at $58.83